![](/images/graphics-bg.png)
Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models
المؤلفون المشاركون
Sugahara, Kunio
Maeda, Yasuhiro
Shimano, Kyoko
Murase, Mikako
Mochiduki, Sachiko
Takemoto, Kana
Kakimoto, Tetsuhiro
Utsumi, Hiroyuki
Oshita, Koichi
Kataoka, Hirotoshi
المصدر
Journal of Immunology Research
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-12-23
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Amiselimod (MT-1303) is a novel and selective sphingosine 1-phosphate receptor-1 (S1P1) modulator with a more favorable cardiac safety profile than other S1P1 receptor modulators.
In this study, we evaluated the effects of MT-1303 on the progression of lupus nephritis in two well-known murine systemic lupus erythematosus (SLE) models, MRL/lpr and NZBWF1 mice, compared with those of FK506.
Daily oral doses of 0.1 and 0.3 mg/kg MT-1303 not only inhibited the development of lupus nephritis when administered before onset in MRL/lpr and NZBWF1 mice but also improved symptoms of lupus nephritis when administered after onset in MRL/lpr mice.
Its efficacy in these models was more potent or comparable to that of FK506 (1 and 3 mg/kg).
In histological analysis, treatment with MT-1303 inhibited infiltration of T cells into the kidneys, mesangial expansion, and glomerular sclerosis.
MT-1303 treatment resulted in a marked reduction in T cells and B cells in the peripheral blood and significantly inhibited increases in the number of plasma cells in the spleen and T cells in the kidneys.
In addition, administration of MT-1303 suppressed elevations in serum anti-dsDNA antibody levels in MRL/lpr mice, but not in NZBWF1 mice.
Our findings show that MT-1303 exhibits marked therapeutic effects on lupus nephritis in two SLE models, likely by reducing the infiltration of autoreactive T cells into the kidneys.
These results suggest that MT-1303 has the potential to be used as a therapeutic agent for patients suffering from SLE, including lupus nephritis.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sugahara, Kunio& Maeda, Yasuhiro& Shimano, Kyoko& Murase, Mikako& Mochiduki, Sachiko& Takemoto, Kana…[et al.]. 2019. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sugahara, Kunio…[et al.]. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sugahara, Kunio& Maeda, Yasuhiro& Shimano, Kyoko& Murase, Mikako& Mochiduki, Sachiko& Takemoto, Kana…[et al.]. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1176370
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)